Genpact LTD current report, 21 November 2019

Genpact Limited Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Genpact Limited on November 21, 2019. The filing reports the entry into a material definitive agreement regarding a secondary offering of common shares by selling shareholders.

Key Financial Metrics

The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a share sale agreement.

Material Changes

  • Secondary Offering: The Company entered into an underwriting agreement for the sale of 15,430,841 common shares by selling shareholders affiliated with Bain Capital Investors, LLC and Twickenham Investment Private Limited.
  • Underwriter: Goldman Sachs & Co. LLC is the sole underwriter for the transaction.
  • Company Proceeds: Genpact Limited is not selling any shares and will not receive any proceeds from this offering.
  • Shareholder Agreement Termination: Upon closing, the selling shareholders will no longer beneficially own any shares. Consequently, the amended and restated shareholders agreement dated October 25, 2012, will terminate automatically.
  • Governance Impact: Following the transaction, the selling shareholders will no longer be entitled to designate directors for nomination to the board of directors or require the filing of registration statements.

Outlook and Risks

The offering is expected to close on November 26, 2019, subject to customary closing conditions. The shares are being offered pursuant to a shelf registration statement effective as of April 22, 2019. No specific risks, contingencies, or management commentary regarding future financial performance are detailed in this specific filing.

Investor Verification Checklist

  • Verify the closing date of the offering (expected November 26, 2019) and the final sale price per share in the prospectus supplement.
  • Confirm the termination of the Shareholder Agreement and the resulting changes to board nomination rights.
  • Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms, conditions, and indemnification clauses.
  • Check subsequent filings to confirm the completion of the transaction and the updated beneficial ownership structure.